Biocon shares surge 3% on integration of Viatris’ biosimilar business in 31 European countries
Biocon Biologics acquired the global biosimilar business of Viatris in November last year.
biocon ltd
December 2023
August 2023
November 2022
Biocon shares down 5% on 30% dip in Q1 profit
Biocon Ltd reported a decline in the net profit in the April to June quarter by 30% to ₹101.4 crore as against ₹144.40 crore in the same period last year.
Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn
Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
